Retension Pharmaceuticals Debuts on US Stock Market, Shares Drop Over 10% After Opening

Stock News

12 hours ago

According to reports, on Friday, Retension Pharmaceuticals Inc (RTSN.US) listed on the US stock market. As of press time, the stock had fallen more than 10% to $10.77. The IPO price was $12.

Retension Pharmaceuticals Inc is a US clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases.

The company's core investigational drug, RTN-001, is a next-generation phosphodiesterase 5 (PDE5) inhibitor primarily targeting patients with inadequately controlled blood pressure and resistant hypertension, and is currently undergoing Phase IIb clinical trials.

The drug works by enhancing nitric oxide signaling in blood vessels, helping to dilate blood vessels and lower blood pressure. Its exclusive global development license was obtained from French pharmaceutical giant Sanofi (SNY.US).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/news/1144830990"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144830990\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144830990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-10 00:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144830990","market":"sg","top_or_hot":-1,"title":"Retension Pharmaceuticals Debuts on US Stock Market, Shares Drop Over 10% After Opening","media":"Stock News","content":"<p>According to reports, on Friday, <b>Retension Pharmaceuticals Inc</b> (<b>RTSN.US</b>) listed on the US stock market. As of press time, the stock had fallen more than 10% to $10.77. The IPO price was $12.<br><br><b>Retension Pharmaceuticals Inc</b> is a US clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases.<br><br>The company's core investigational drug, RTN-001, is a next-generation phosphodiesterase 5 (PDE5) inhibitor primarily targeting patients with inadequately controlled blood pressure and resistant hypertension, and is currently undergoing Phase IIb clinical trials.<br><br>The drug works by enhancing nitric oxide signaling in blood vessels, helping to dilate blood vessels and lower blood pressure. Its exclusive global development license was obtained from French pharmaceutical giant Sanofi (SNY.US).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Retension Pharmaceuticals Debuts on US Stock Market, Shares Drop Over 10% After Opening</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRetension Pharmaceuticals Debuts on US Stock Market, Shares Drop Over 10% After Opening\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-10 00:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to reports, on Friday, <b>Retension Pharmaceuticals Inc</b> (<b>RTSN.US</b>) listed on the US stock market. As of press time, the stock had fallen more than 10% to $10.77. The IPO price was $12.<br><br><b>Retension Pharmaceuticals Inc</b> is a US clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases.<br><br>The company's core investigational drug, RTN-001, is a next-generation phosphodiesterase 5 (PDE5) inhibitor primarily targeting patients with inadequately controlled blood pressure and resistant hypertension, and is currently undergoing Phase IIb clinical trials.<br><br>The drug works by enhancing nitric oxide signaling in blood vessels, helping to dilate blood vessels and lower blood pressure. Its exclusive global development license was obtained from French pharmaceutical giant Sanofi (SNY.US).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RTSN","symbol_name":"Retension Pharmaceuticals Inc","start_time":0,"source_url":"","article_id":"1144830990","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144830990","pubTimestamp":1791563294,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to reports, on Friday, Retension Pharmaceuticals Inc (RTSN.US) listed on the US stock market. As of press time, the stock had fallen more than 10% to $10.77. The IPO price was $12.Retension...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RTSN":"Retension Pharmaceuticals Inc","MRNX":"Defiance Daily Target 2X Long MRNA ETF","03069":"华夏恒生生科","BK1610":"ETF&股票定投概念","BBP":"Virtus LifeSci Biotech Products ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","MRNY":"MRNA期权收益策略ETF-YieldMax"},"translate_title":"Retension Pharmaceuticals登陆美股，开盘后股价下跌超10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RTSN":1,"MRNY":1,"03069":1,"BBP":1,"MRNX":1,"IBBQ":1},"content_text":"According to reports, on Friday, Retension Pharmaceuticals Inc (RTSN.US) listed on the US stock market. As of press time, the stock had fallen more than 10% to $10.77. The IPO price was $12.Retension Pharmaceuticals Inc is a US clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases.The company's core investigational drug, RTN-001, is a next-generation phosphodiesterase 5 (PDE5) inhibitor primarily targeting patients with inadequately controlled blood pressure and resistant hypertension, and is currently undergoing Phase IIb clinical trials.The drug works by enhancing nitric oxide signaling in blood vessels, helping to dilate blood vessels and lower blood pressure. Its exclusive global development license was obtained from French pharmaceutical giant Sanofi (SNY.US).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}